Spyre Therapeutics, Inc. - Common Stock SYRE 深 沪
等待开盘 12-26 09:30:00 美东时间
33.05
-0.180
-0.54%
华盛通- 最 高34.10
- 今 开33.38
- 成交量 29.20万股
- 最 低 32.79
- 昨 收 33.23
- 总市值 25.64亿
- 52周最高 35.31
- 市盈率 静 --
- 换手率 0.38%
- 52周最低 10.91
- 委 比 30.72%
- 总股本 7759.21万
- 历史最高 318.75
- 量 比 0.21
- 振 幅 3.94%
- 历史最低 2.66
- 每 手 1
- 风险率 5.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
12-19 10:15
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
12-18 10:54
Citigroup Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $64
Citigroup analyst Samantha Semenkow initiates coverage on Spyre Therapeutics (NASDAQ:SYRE) with a Buy rating and announces Price Target of $64.
12-17 23:11
美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
12-02 09:50
Jones Trading Upgrades Spyre Therapeutics to Buy, Announces $64 Price Target
Jones Trading analyst Debanjana Chatterjee upgrades Spyre Therapeutics (NASDAQ:SYRE) from Hold to Buy and announces $64 price target.
12-01 21:17
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
<p>Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotech company focused on long-acting antibodies for inflammatory bowel disease and rheumatic diseases, announced that its management will attend three upcoming investor conferences in November 2025. The events include the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, the Stifel 2025 Healthcare Conference in New York, and the Jefferies Global Healthcare Conference i...
10-29 20:05
Spyre Therapeutics Releases New Data From Its Phase 1 Study Of SPY072, An anti-TL1a Antibody For Rheumatic Diseases Showing SPY072 Was Well Tolerated, Maintained Strong Tl1a Suppression, And Supports Quarterly Or Twice-Yearly Dosing
Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease ("IBD") and
10-24 20:04
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
Spyre Therapeutics announced scientific presentations at the ACR Convergence Congress, sharing Phase 1 data on SPY072, an anti-TL1A agent for rheumatic diseases. The data showed SPY072 is well-tolerated, with a PK profile supporting quarterly or twice-yearly dosing, and suppressed free TL1A at the lowest dose. Additionally, preclinical data demonstrated SPY072's efficacy, meeting or exceeding etanercept in a rodent arthritis model, supporting ong...
10-24 12:00
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
Spyre Therapeutics, a clinical-stage biotech company focused on treating inflammatory bowel disease and other immune-mediated conditions, announce the closing of its underwritten public offering. The company sold 17,094,594 shares, including 2,229,729 additional shares due to underwriters' option exercise, at $18.50 per share, resulting in approximately $316.2 million in gross proceeds. Jefferies, TD Securities, Leerink Partners, and Stifel acted...
10-15 20:15
Spyre Therapeutics Reveals Proposed Public Offering of its Common Stock And Pre-Funded Warrants; No Size Disclosed
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization,
10-14 04:03
